A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron
A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron
Bispecific antibodies have emerged as a promising strategy for curtailing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape. This brief report highlights RBT-0813 (also known as TB493-04), a synthetic, humanized, receptor-binding domain (RBD)-targeted bispecific antibody that retains picomolar affinity to the Spike (S) trimers of all major variants of concern and neutralizes both SARS-CoV-2 Delta and Omicron in vitro.
Yuan Tom Z.、Lucas Carolina、Monteiro Valter S.、Nepita Hector F.、Lujan Hernandez Ana G.、Weber C¨|dric R.、Sato Aaron K.、Iwasaki Akiko、Taft Joseph M.、Reddy Sai T.、Yang Marisa L.、Malobisky Kevin P.、Frei Lester、Mesquita Rodrigo
Twist Biopharma, Twist BioscienceSchool of Medicine, Yale UniversitySchool of Medicine, Yale UniversityTwist Biopharma, Twist BioscienceTwist Biopharma, Twist BioscienceAlloy TherapeuticsTwist Biopharma, Twist BioscienceSchool of Medicine, Yale University||Howard Hughes Medical InstituteDepartment of Biosystems Science and Engineering, ETH ZurichDepartment of Biosystems Science and Engineering, ETH ZurichTwist Biopharma, Twist BioscienceRevelar Biotherapeutics, IncDepartment of Biosystems Science and Engineering, ETH ZurichRevelar Biotherapeutics, Inc
医学研究方法基础医学生物科学研究方法、生物科学研究技术
VHHSARS-CoV-2COVID-19DeltaOmicronsyntheticbispecificSpike
Yuan Tom Z.,Lucas Carolina,Monteiro Valter S.,Nepita Hector F.,Lujan Hernandez Ana G.,Weber C¨|dric R.,Sato Aaron K.,Iwasaki Akiko,Taft Joseph M.,Reddy Sai T.,Yang Marisa L.,Malobisky Kevin P.,Frei Lester,Mesquita Rodrigo.A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron[EB/OL].(2025-03-28)[2025-05-18].https://www.biorxiv.org/content/10.1101/2022.01.04.474803.点此复制
评论